Video

How to Assess Your Risk of Breast or Ovarian Cancer

Author(s):

Bright Pink

One in 8 women will be diagnosed with breast cancer. It is the leading cancer diagnosis in women. And, while less common, 1 in 75 women will be diagnosed with ovarian cancer and two-thirds will lose their life as a result of their diagnosis. However, when caught early, the 5-year survival rate for breast and ovarian cancer is greater than 93 percent.

Visit Assess Your Risk and take a 19-question quiz to better understand your baseline risk of breast and ovarian cancer.

Bright Pink, a national nonprofit focused on the prevention and early detection of breast and ovarian cancer, wants to help you understand how your personal health history, family health history, and lifestyle all work together to influence your risk of these cancers.

Related Videos
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Image of man with grey hair.
Image of woman with blonde hair.
Related Content
An expert discusses the FDA approval of Enhertu in unresectable or metastatic HR+, HER2-low or -ultralow breast cancer: © stock.adobe.com
February 19th 2025

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

Ryan Scott
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of Randy Moss Photo credit: Jonathan Bachman - Getty Images
February 7th 2025

Randy Moss Shares Cancer Update, “Squid Game” Star Dies and More

Alex Biese
From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of patient with breast cancer and oncologist.
February 4th 2025

A Patient-Centered Approach to Plastic Surgery Reconstruction

SurvivingBreastCancer.org (SBC)
Breast cancer surgery is a deeply personal and often challenging experience for many women.
Image of patients with breast cancer
February 4th 2025

Nutrition After a Cancer Diagnosis

Surviving Breast Cancer
If you’re reading this, you recognize the importance of diet and nutrition after a cancer diagnosis.